Merit Medical Systems
The 10-second takeaway
For the quarter ended Sep. 30 (Q3), Merit Medical Systems missed estimates on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue grew and GAAP earnings per share expanded significantly.
Gross margins expanded, operating margins dropped, net margins grew.
Merit Medical Systems chalked up revenue of $95.9 million. The five analysts polled by S&P Capital IQ predicted revenue of $98.6 million on the same basis. GAAP reported sales were 6.0% higher than the prior-year quarter's $90.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.20. The five earnings estimates compiled by S&P Capital IQ forecast $0.16 per share. GAAP EPS of $0.17 for Q3 were 55% higher than the prior-year quarter's $0.11 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 47.3%, 190 basis points better than the prior-year quarter. Operating margin was 9.8%, 120 basis points worse than the prior-year quarter. Net margin was 7.5%, 250 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $101.4 million. On the bottom line, the average EPS estimate is $0.19.
Next year's average estimate for revenue is $396.1 million. The average EPS estimate is $0.74.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 87 members out of 92 rating the stock outperform, and five members rating it underperform. Among 24 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 24 give Merit Medical Systems a green thumbs-up, and give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Merit Medical Systems is outperform, with an average price target of $15.67.
- Add Merit Medical Systems to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.